Invokana® (canagliflozin): Advice on the risk of lower limb amputation (primarily of the toe) during treatment with canagliflozin-containing medicines

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive
 

Date: 25 August 2016

 

Description:

Tarceva® (erlotinib) is no longer indicated for the first-line maintenance treatment in patients without an epidermal growth factor receptor (EGFR)-activating mutation based on data from the IUNO study. The results of the IUNO study led to the conclusion that the benefit-risk of Tarceva® is no longer considered favourable for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after 4 cycles of standard platinum-based first-line chemotherapy whose tumours do not harbour an EGFR-activating mutation. Please refer to the DHPC issued by Roche (Malaysia) Sdn. Bhd. for further information.

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

Image   Image   Image   Image  

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Wednesday 27 March 2024, 22:44:22.
© Copyright 2023 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Search

Main Menu English